Jayesh Mehta, MD, professor of medicine (hematology and oncology), Feinberg School of Medicine, discusses stem cell transplant in multiple myeloma.

Many people do not like stem cell transplantation, but studies show that eliminating it from treatment only hurts the patient, says Mehta.

With curable diseases with different pathways, it is acceptable to choose 1 form of treatment over another, but that is not the case for incurable diseases, explains Mehta.

Videos

Dr. Mehta on Stem Cell Transplant in Multiple Myeloma

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

In relapsed disease, it has been concluded that 3-drug regimens are better than 2-drug combinations. But, whether they are truly better in patients who may or may not undergo transplant is unclear, says Mehta.

This poses the question of giving more drugs upfront, or introducing drugs later in the disease course. Adding more drugs also brings up the question of cost.

Jayesh Mehta, MD

Articles

Dr. Mehta on Stem Cell Transplant in Multiple Myeloma

Dr. Mehta Discusses Combinations in Multiple Myeloma